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The C-MYB locus is involved in chromosomal translocation and genomic 
duplications in human T-cell acute leukemia (T-ALL) – the translocation defining 
a new T-ALL subtype in very young children 
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Abstract  
 
The c-Myb transcription factor is essential for primitive and adult hematopoiesis, 
including in the T-cell lineage. The c-myb locus is a common site of retroviral 
insertional mutagenesis, however no recurrent genomic involvement has been 
reported in human malignancies. Here, we identified two types of genomic alterations 
involving the C-MYB locus at 6q23 in human T-cell acute leukemia (T-ALL). First, we 
found a reciprocal translocation, t(6;7)(q23;q34), that juxtaposed the TCRB and C-
MYB loci (n=6 cases). Second, a genome wide copy-number analysis by array-CGH 
identified short somatic duplications which include C-MYB (MYB
dup, n=13 cases out of 
84 T-ALL, 15%). Expression analysis, including allele-specific approaches, showed 
stronger C-MYB expression in the MYB-rearranged cases compared to other T-ALLs, 
and a dramatically skewed C-MYB allele expression in the TCRB-MYB cases which 
suggests that a translocation-driven deregulated expression may overcome a cellular 
attempt to downregulate C-MYB. Strikingly, profiling of the T-ALLs by clinical, genomic 
and large-scale gene expression analyses shows that the TCRB-MYB translocation 
defines a new T-ALL subtype associated with a very young age for T-cell leukemia 
(median 2.2 years-old) and with a proliferation/mitosis expression signature. By 
contrast, the MYB
dup alteration was associated with the previously defined T-ALL 
subtypes. 
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Introduction 
C-Myb is a leucine zipper transcription factor, the expression of which is associated 
with immature and proliferative cellular stages and turned off during the maturation of 
the hematopoietic lineage.
1,2 Silencing strategies in mice have shown that c-Myb plays 
a major role in early and definitive hematopoiesis, including lineage commitment, 
proliferation and differentiation.
3-6 In the T-cell lineage, c-Myb is involved at several 
key steps throughout the maturation process.
7-11 The c-Myb gene was first identified 
as the cellular homologue of the transforming v-Myb gene of two avian retroviruses 
that induce leukemia, AMV and E26.
12-15 Transgenic expression of v-Myb, which is a 
truncated and mutated form of mammalian c-Myb, induces lymphoid or myeloid 
tumors in mice.
16,17 The murine c-Myb locus is also a common site of retroviral 
insertion in lymphoid and myeloid leukemia.
18-23 In human, the C-MYB gene is located 
at chromosomal band 6q23.3, and interestingly the chromosome 6q is frequently 
involved in chromosomal abnormalities in human cancer, including hematological 
malignancies.
24 In addition, C-MYB is frequently expressed in human cancer.
14,25-27 
However, despite intensive studies in a large range of human neoplasia including 
leukemia, no clear recurrent involvement of the C-MYB locus in genomic abnormalities 
has been reported to date.
23,28-31  
T-cell acute lymphoblastic leukemias (T-ALL) are highly malignant tumors that derive 
from T-cell progenitors.
32-34 Immunophenotypic and gene expression analyses of 
leukemic cells have revealed heterogeneity that partially reflects distinct stages of T-
cell maturation arrest.
35-38 Correlations between oncogene expression, 
immunophenotype, and large-scale expression profiles have allowed the definition of 
distinct oncogenic T-ALL subtypes.
37,38 Genetic studies have pointed out an increasing 
number of oncogenes in T-ALLs, further demonstrating the complexity of T-ALL 
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oncogenesis and the requirement for several cooperative oncogenic events.
33,34,38 T-
ALL oncogenes include aberrantly activated transcription factor, namely bHLH (TAL1, 
TAL2, LYL1, and BHLHB1), LIM-only genes (LMO1 and LMO2),  homeobox genes 
(HOXA, TLX1/HOX11,  TLX3/HOX11L2, NKX2-5), and the CALM-AF10 and MLL 
fusion genes.
33,34,38-42 In addition, the tumor suppressor locus CDKN2A/p16/ARF is 
inactivated in most T-ALL cases,
43,44 and NOTCH1 is activated by mutations in half the 
cases.
45,46 The Cyclin D2 gene, and the NUP214-ABL1 fusion can also be involved in 
multistep oncogenesis.
47,48 Notably, most T-ALL oncogenes were identified initially by 
their involvement in recurrent genomic abnormalities. It is expected that the 
identification of genetic lesions underlying each subtype of T-ALL will help to adapt 
therapy, including the development of specific agents against oncogenic pathways – 
so-called targeted therapy.
49  
Using combined cytogenetic, genomic and molecular tools, we demonstrate for the 
first time a clear recurrent genomic involvement of the C-MYB gene locus at 6q23.3 in 
a human cancer, namely T-ALL, by two distinct types of somatic alteration: TCRB-
related translocation and cryptic duplication of a short genome region. Expression 
analysis suggested that a deregulated C-MYB expression may be oncogenic in T-ALL. 
Moreover, the t(6;7) TCRB-MYB translocation defines a new T-ALL subtype which is 
associated with a very young age and a proliferation/mitosis expression signature.  
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Patients, Materials and Methods 
Patient samples and molecular annotations 
A series of 92 T-ALL patients (56 children, 36 adults) were diagnosed and treated at 
Saint-Louis Hospital, Paris, France. The patients’ age at diagnosis ranged from 13 
months to 66 years (median age, 15 years). Informed consent was obtained from the 
patients or relatives. The study was approved by the Hopital Saint-Louis and Institut 
Universitaire d’Hematologie Institutional Review Board.  Four T-cell lines, CCRF-CEM, 
HSB-2, Jurkat and MOLT-4 were included in the analysis. This series was previously 
characterized for oncogene expression and classified for oncogenic groups according 
to combined immunophenotypic data, oncogene expression, and global gene 
expression analysis using Affymetrix data.
38 Three additional T-ALL cases were added 
to this series, one from Saint-Louis Hospital (TL93) and two that were analyzed by 
W.A.D. and A.W.L. (T142), and B.M. and B.N. (UPN5846). Large-scale expression 
data were obtained for case TL93 and were used after normalization using previously 
described methods
38 for a new global analysis. The array-based Comparative 
Genomic Hybridization (array-CGH) study was performed on 84 samples with 
available material out of the 92 initial cases (80 T-ALL cases and the 4 T-cell lines), as 
part of the CIT National French programme. Constitutional genomic DNA was 
obtained from follow-up samples of six patients in complete remission; these DNA 
samples were used as paired controls in array-CGH experiments to rule out copy 
number polymorphisms. Additional T-ALL oncogenic annotations were obtained as 
follows:  CDKN2A/p16/ARF genomic data using array-CGH analysis and/or locus-
specific FISH, and NOTCH1 mutations by sequencing PCR-amplified genomic 
fragments of exons 26, 27 and 34 (encoding the heterodimerization domain (HD) and 
the PEST domain.
45  
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Cytogenetic and molecular analyses 
Interphasic fluorescence in situ hybridization (FISH) analyses were performed on 
cryopreserved leukemic cells. All FISH probes were prepared from BAC (Bacterial 
artificial chromosome) or PAC (P1-derived artificial chromosome) clones obtained 
from the BAC/PAC Resource Center at Children's Hospital Oakland Research Institute 
Oakland, California (http://bacpac.chori.org). Whole chromosome painting FISH was 
performed using WCP6 and WCP7 from Abbott Laboratories (http://www.vysis.com). 
The TCRB-flanking FISH probes have been described previously.
38 The C-MYB locus 
FISH probes were RP11-845K5, RP11-184J4, RP11-104D9, RP11-141K5, RP11-
55H4, and RP11-166A21. For Fiber-FISH analysis, DNA combed preparations were 
performed using Molecular Combing Apparatus
TM (Institut Pasteur, Paris) as 
described.
50 Southern blot analysis for the C-MYB locus was performed using EcoRI, 
HindIII and XbaI digestions and a panel of PCR-amplified probes from BAC RP3-
388E23 DNA. Molecular cloning of the TCRB translocation breakpoint sequences was 
performed using ligation-mediated PCR methods as previously reported.
38  
Genome wide array-CGH analysis 
A 4K BAC-PAC array-CGH (Curie Institute - French Ligue Contre le Cancer, Paris, 
France) was used on 84 T-ALL samples. This array contained 3,922 BAC and PAC 
DNAs, as previously described.
51 This array was designed to regularly cover the 
genome and also included additional clones for putative oncogenes such as C-MYB, 
or for regions known to be commonly rearranged in cancer. Hybridization, scanning, 
normalization, and data analysis were performed using standard procedures.
51 
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High-density 244K oligonucleotide arrays (Agilent Technologies, www.agilent.com) 
were used to map the C-MYB duplication precisely, and to confirm somatic gain in 
paired tumor and constitutional genomic DNA from the same patients in cases TL29 
and TL59. 
Genomic databases and bioinformatics tools 
The following databases and tools were used : the UCSC Genome Browser 
(http://genome.ucsc.edu), Ensembl (http://www.ensembl.org/index.html ) 
, the Immunogenetics (IMGT) repertoire for immunoglobulins and T cell receptors 
(http://imgt.cines.fr/textes/IMGTrepertoire), the NCBI blast tools 
(http://ncbi.nlm.nih.gov/blast), the Mitelman Database of Chromosome Aberrations in 
Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman), the Database of Genomic 
Variants (http://projects.tcag.ca/variation), the Mouse Retrovirus Tagged Cancer Gene 
Database (http://rtcgd.ncifcrf.gov), the Entrez databases 
(http://www.ncbi.nlm.nih.gov/), and the Gene Ontology project database 
(http://www.geneontology.org). 
Array-CGH data were analyzed using the Curie Institute VAMP tools
52 
(http://www.curie.fr/recherche/themes/detail_equipe.cfm/lang/_gb/id_equipe/303.htm) 
and the CGH Analytics 3.2 software (Agilent Technologies, www.agilent.com).  
Large-scale gene expression data were normalized, and the analysis was performed 
using dChip (www.dchip.org), as previously described.
38  
C-MYB expression and sequence analyses 
RNA samples were reverse transcribed and cDNAs were analyzed for C-MYB 
transcripts by real-time quantitative PCR (RQ-PCR) using Taqman
TM methods 
(Applied Biosystems, www.appliedbiosystems.com/). Results were normalized on 
expression of the housekeeping gene TBP, according to the formula: level of C-MYB = 
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2
[CtTBP-CtMYB]. RQ-PCR system for analysis of MYB expression was as follows, MYB-F: 
5’-CTATTACCACATTTCTGAAGCACAAAA-3’, MYB-R: 5’-
GCTGAGGGACATTGACTATATTTACATG-3’, and MYB probe: 5’-6-FAM-
CTCCAGTCATGTTCCATACCCTGTAGCGTT-TAMRA-3’;  TBP housekeeping gene: 
TBP-F: 5’-  CACGAACCACGGCACTGATT-3’, TBP-R: 5’-
TTTTCTTGCTGCCAGTCTGGAC-3’, and TBP probe: 5’-6-FAM-
TGTGCACAGGAGCCAAGAGTGAAGA-TAMRA-3’. Additional PCR systems for the 
analysis of alternative transcripts and differential use of promoters are shown in the 
Supplemental Figure S4. In selected cases, the entire C-MYB open reading frame was 
sequenced on both strands from leukemic cDNA after PCR of cDNA from leukemic 
cells; primers sequence are available in Supplemental Figure S4. A polymorphic poly-
T (T8/9) microsatellite found in the 3’-UTR region was used for analysis of C-MYB 
allelic expression. Fragment size analysis of a fluorescent-labeled PCR fragment 
using Genescan
TM methods (Applied Biosystems) allowed discrimination of the T8/T9 
alleles. PCR primers were as follows: S217F-5’-6-FAM-
AGGTAATGAATTGTAGCCAG-3’ and S218R-5’-AAATACTGATCTGTTGGATCC-3’. 
Leukemic genomic DNA samples were first analyzed to determine the heterozygous 
cases, and then leukemic cDNAs from informative cases were analyzed to determine 
C-MYB allele expression. 
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Results 
Identification of a recurrent translocation t(6;7)(q23;q34) in T-ALL involving the 
TCRB and C-MYB loci 
In the course of conventional cytogenetic analysis at diagnosis of acute leukemia 
patients in Saint-Louis Hospital, we identified a chromosomal translocation 
t(6;7)(q23;q34) in two pediatric T-ALL cases (TL34 and TL92, Figure 1A and 1B). 
Dual-color FISH using TCRB flanking probes demonstrated involvement of the TCRB 
locus at 7q34 in both cases (Figure 1B). By using inverse PCR from the TCRB 
sequence, we amplified and characterized the breakpoints derivative sequences in 
case TL34 (Figure 1C). The breakpoint on chromosome 6q23.3 was mapped in the 
vicinity of the C-MYB oncogene. Probes were derived from the C-MYB locus and 
demonstrated in FISH and Southern blot experiments that the same locus was 
involved in case TL92 (Figure 1D). The t(6;7)(q23;q34) involves telomeric regions in 
both chromosomes 6 and 7, hence we assumed that this translocation could have 
been missed in systematic T-ALL karyotype series. We therefore used C-MYB flanking 
FISH probes which allowed us to identify two additional cases with translocations 
involving the C-MYB and TCRB loci (TL33 and TL93, Figure 1E) from a series of 84 T-
ALL (80 T-ALL patients and 4 T-cell lines). Finally, two isolated cases with a TCRB-
MYB translocation (UPN5846 and T142) were detected from independent T-ALL 
series by systematic molecular analysis of oncogenic TCRB genes rearrangements, 
as performed by B.M. and B.N., and W.A.D. and A.W.L. These cases were added to 
the present study, giving a total of six TCRB-MYB cases, including three cases fully 
characterized at the molecular level on both derivative chromosomes (Figure 1C and 
Supplemental Fig S1). Sequence analysis of the TCRB derivative sequences were 
suggestive of a specific mechanism of V(D)J-mediated translocation typically seen at 
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the TCRB locus.
53,54 These translocations were reciprocal and balanced, and led to 
the juxtaposition of the C-MYB proto-oncogene near to the TCRB regulatory sequence 
(Figure 1F), which suggested deregulated expression. 
  
A genome-wide array-CGH screen in T-ALL identified recurrent somatic genomic 
duplications at the C-MYB locus 
A genome-wide analysis of genomic copy number was performed in 84 out of the 92 
T-ALL cases (80 primary samples and four T-cell lines), in order to detect genomic 
imbalances in T-ALL. Leukemic DNA samples and a normal DNA XY control (GYPT) 
were co-hybridized on a 4K BAC/PAC array (see Materials and Methods). 
Remarkably, examination of the data for chromosome 6 revealed a DNA copy gain of 
a 6q23.3 region in 13 cases out of 84 T-ALL (11 T-ALL patients and 2 T-cell lines, 
Figure 2A). In two cases, the DNA copy gain consisted of a large chromosomal gain 
(6.0 Mb in TL01, and 22.4 Mb in TL76), while in the other cases the amplified region 
was restricted to a region <2 Mb including the C-MYB locus. The MOLT4 cell line 
showed a more complex profile with a gain of a large region of chromosome 6q in a 
pseudotetraploid karyotype reinforced by higher level of amplification in a region <2 
Mb at the C-MYB locus (Figure 2A, top panel).  
We then investigated whether the short DNA copy gain of the C-MYB locus was a 
somatic rearrangement that originated in leukemic cells, or whether it could be a 
constitutional large-size copy number variation (CNV) as was recently reported in the 
human genome.
55-57 Notably, no CNV was reported in this region in the Database of 
Genomic Variants (Supplemental Figure S2). Then we compared our data to those 
from two independent array-CGH studies on breast cancer samples that were 
performed using the same array and the same control DNA (GYPT, a unique XY 
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healthy subject whose DNA was used in several studies); no recurrent genomic 
imbalance in the C-MYB locus was observed in these other studies, which suggested 
that there was no frequent CNV in this region and that the C-MYB gain was associated 
with T-ALL (data not shown). Finally, we were able to demonstrate definitively the 
somatic origin of the C-MYB gain by co-hybridizing on the same array paired leukemic 
and constitutional DNAs from the same patient in two T-ALL cases with available 
constitutional material (Figure 2B).  
Thereafter, we defined a minimal region of DNA copy gain using high density 244K 
oligonucleotide array-CGHs (Agilent) to a consistent region of length approximately 
230 kb including the C-MYB gene (Figure 2C). A panel of probes covering the C-MYB 
locus detected no extra signal in metaphases or interphase nuclei in cases with C-
MYB  copy gain (Figure 2D), which suggests a local duplication. That was 
demonstrated by fiber-FISH analysis showing a direct tandem duplication of the C-
MYB locus (Figure 2E). Cases with C-MYB locus duplication are further referred to in 
the study reported herein as MYB
dup cases. 
 
Genomic location of the C-MYB locus rearrangements in human and mouse T-
cell leukemias 
In the present study two types of recurrent somatic rearrangement were identified in T-
ALL, namely reciprocal chromosomal translocation TCRB-MYB, and short genomic 
duplications MYB
dup, which target a unique 6q23.3 region that includes the C-MYB 
proto-oncogene. Molecular mapping of the six t(6;7)(q23;q34) chromosomal 
breakpoints, which included complete breakpoint sequencing in three cases (TL34, 
T142, and UPN5846), showed two discrete breakpoint clusters at 6q23.3 (Figure 3, 
upper panel); one located 5 kb telomeric, 3’ of the C-MYB gene (4 cases, TL33, TL93, 
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T142 and UPN5846), and the other 50 kb more telomeric (2 cases, TL34 and TL92). 
In all cases, the translocation placed the C-MYB proto-oncogene in the vicinity of the 
TCRB regulatory sequence, which suggests that abnormal regulation of C-MYB 
expression could confer oncogenic properties. The 6q23 genomic duplication was 
mapped to a short region of approximately 230 kb that encompassed the entire C-
MYB gene in all duplicated cases (Figure 3, upper panel), which reinforced the view of 
a targeting of this gene by oncogenic somatic events in T-ALL. Another gene, known 
as AHI1, was located in the vicinity of the t(6;7) breakpoints and was disrupted in two 
out of six cases with the t(6;7), but not in the other four cases. It was also partially 
included in the minimal region of duplication.  
Reminiscent of the 6q23 rearrangements that we identified in human T-ALL, the c-Myb 
locus is known to be a frequent insertion site in retrovirally induced leukemias. The 
lower panel of figure 3 shows the insertion sites in murine T-cell leukemia as reported 
in the Retrovirus Tagged Cancer Gene Database.
19,21-23 These sites are distributed 
around the c-Myb gene, within a region that extends from approximately 100 kb 
upstream to 150 kb downstream of the gene. Importantly, insertion sites flank both 
sides of c-Myb, which suggests that this gene is an oncogenic target in this 
chromosomal region. 
Therefore the combined genomic data from human (present study) and murine T-cell 
leukemias (from previous reports), demonstrate that this locus is recurrently targeted 
in T-cell oncogenesis, and point to the C-MYB gene as a strong candidate oncogene 
in these T-ALL cases.  
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C-MYB expression analysis in human T-ALLs  
The murine c-Myb gene has been shown to be strongly expressed in normal thymus, 
and it is necessary for progression through several stages of T-cell differentiation.
7-11 
To gain insights in the putative oncogenic role of C-MYB rearrangements in human T-
ALL, we analyzed C-MYB expression using real-time quantitative PCR (RQ-PCR) in 
the MYB-rearranged T-ALL cases in comparison with other T-ALL cases and control 
cells. We found strong C-MYB expression in the T-ALL cases (i.e. not only in the 
rearranged cases), compared to normal PHA-stimulated PBL, normal bone marrow, 
and growing fibroblasts (Figure 4A). In this high range, the median expression of C-
MYB transcripts was stronger in the t(6;7) and MYB
dup cases than in other T-ALLs 
(Figure 4A). Consistent results were obtained by analyzing C-MYB expression from 
large-scale expression data, whereas no difference was found for the other genes of 
the region among the T-ALL groups (Supplemental Figure S3). An analysis was 
performed using RQ-PCR systems that were designed to evaluate several alternative 
transcripts (see Supplemental Figure S4). Systems included the main C-MYB 
transcripts, long variant transcripts that include the so-called alternative exon 9A, the 
use of distinct promoters (an alternative transcription site has been reported just 
upstream of exon 2 in human and mouse), the use of the 3’UTR region in Exon 15. 
Also standard RT-PCR was performed to search for additional small exons. This 
analysis did not reveal changes in the differential pattern of alternative transcripts in 
the MYB-rearranged cases compared to other T-ALL cases and normal controls, nor 
did it reveal additional exons (Supplemental Figure S4). C-MYB immunoblot analysis 
of a number of T-ALL primary cases and cell lines did not reveal aberration of C-MYB 
levels or size (Supplemental Figure S4). Then we sequenced the C-MYB open reading 
frame from leukemic cDNA in two t(6;7) cases (TL34, TL92) and in the four T-cell lines 
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including the two MYB
dup cell lines (CCRF-CEM and MOLT4), and no mutation was 
found. At this point we investigated C-MYB allelic expression in the T-ALL leukemic 
cells, taking advantage of a T8/T9 polymorphic repetition in the 3’UTR of the C-MYB 
gene (Figure 4B). Forty-one cases out of 84 T-ALLs showed a heterozygous T8/T9 
polymorphism in leukemic genomic DNA and were therefore informative, including 
three  TCRB-MYB cases (TL33, TL34, and TL92) and seven MYB
dup  cases (TL01, 
TL29, TL38, TL49, TL61, TL76, and MOLT4). Strikingly, analysis at the RNA level 
demonstrated a dramatically imbalanced C-MYB expression in the three TCRB-MYB 
cases, suggesting a skewed TCRB-driven expression and, importantly, a low 
expression of the other allele (Figure 4B and 4C). In the seven informative MYB
dup 
cases, allelic expression of C-MYB was imbalanced in the same way as genomic DNA 
copy number, or even more in some cases (figure 4C). By contrast, a balanced C-
MYB expression was found in all non-rearranged T-ALL cases (n=27 informative 
cases, Figure 4C). In all, our data suggest that the expression of C-MYB transcripts 
can be sustained inappropriately at strong levels due to the translocation in the TCRB-
MYB cases, and reinforced due to copy number increase in the MYB
dup cases. 
 
The TCRB-MYB translocation defines a new distinct T-ALL oncogenic subtype, 
associated with very young age and a proliferation/mitosis signature by 
microarray large-scale expression analysis, whereas the MYB
dup is found in 
other T-ALL subtypes 
Clinical and biological data were collected for patients with C-MYB rearrangements 
(Table 1). Strikingly, five out of the six cases with the translocation t(6;7) were 
diagnosed in very young children (1.1, 1.3, 1.8, 2.5, and 2.9 years old, see Table 1; 
median age of the TCB-MYB patients, 2.2). This clustered age range is very unusual 
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in T-ALL where patients are generally older than in precursor B-ALL. For comparison, 
the median age in pediatric T-ALL was 9.4 (range 1 to 19.5) in the French randomized 
multicentric pediatric trials FRALLE 93 and FRALLE 2000 (n=355 pediatric T-ALL 
patients), and only 26 out of 355 children (7.3%) were under three years old (p<0.001). 
Such a unifying feature associated with the TCRB-MYB translocation suggests 
strongly that it defines a new distinct entity in T-ALL. Consistently, the common 
oncogenic abnormalities defining other T-ALL subtypes were not found in the TCRB-
MYB patients, i.e. SIL-TAL, TLX3/HOX11L2, TLX1/HOX11, HOXA, MLL and CALM-
AF10 (Table 1). As in other oncogenic subtypes, the TCRB-MYB cases frequently 
displayed the common additional genomic events, CDNK2A/p16/ARF deletion and 
NOTCH1 mutations, which demonstrates genetic multi-event oncogenesis in this new 
T-ALL subtype (Table 1). 
The situation was clearly different in T-ALL patients with genomic C-MYB duplication. 
Patients had various ages (median 17 years old, range 5 to 52; see Table 1). The 
MYB
dup leukemic cells frequently expressed various other oncogenic transcripts: SIL-
TAL (cases TL29 and CCRF-CEM), TLX1 (TL49, TL59), TLX3 (TL61, TL63, TL66), 
MLL-ENL (TL38), and CALM-AF10 (TL40), and two cases were classified as Immature 
(TL76 and TL77). Additional genomic events were also found in the MYB
dup cases: 
CDNK2A/p16/ARF deletion, NOTCH1 mutations, and NUP214-ABL1 amplification 
(Table 1).  
In order to characterize further the MYB-rearranged T-ALL, we analyzed large-scale 
gene expression data. Three cases with the TCRB-MYB rearrangement (TL33, TL34, 
and TL92), and all MYB
dup cases have been previously included in a series of large-
scale gene expression analysis experiments.
38 A fourth case (TL93) was also tested 
and included in a new global analysis. The MYB-rearranged cases, as other T-ALL, 
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displayed high expression of Cyclin D3
58 and of genes belonging to a global T-ALL 
signature
59 (data not shown). An unsupervised classification was performed 
demonstrating that the four TCRB-MYB cases clustered closely (Supplemental Figure 
S5). These cases were then compared by t-test analysis to the three major T-ALL 
subtypes as defined by the molecular abnormalities SIL-TAL1, TLX1, and TLX3. A 
large number of differentially expressed probe sets was obtained in each comparison 
(median p value 4x10
-4,  median
  FDR <10%). A merged list of genes was built 
(Supplemental Table ST1), and hierarchical clustering analysis was performed. The 
four TCRB-MYB cases stably co-clustered with three cell lines, namely Jurkat, CCRF-
CEM and MOLT4, the thymus sample, and the SIL-TAL case TL29 (Figure 5A). This 
cluster was included in a large branch that contains all cases with a SIL-TAL1 
rearrangement. The cluster was characterized by high expression of 19 genes (Figure 
5B), 18 of them linked by Gene Ontology (GO) terms to cell cycle, mitosis and cell 
proliferation (Supplemental Table ST2). Interestingly, no expression of the ectopic 
genes previously associated with the SIL-TAL1, TLX1 or TLX3 subtypes was found in 
any of the 4 cases. By contrast, the MYB
dup cases were distributed in the clusters 
according to oncogene expression (SIL-TAL1, TLX1, TLX3, CALM-AF10, MLL, 
Immature), and they did not cluster together (Supplemental Figure S5).  
These data show that the TCRB-MYB translocation defines a new T-ALL subtype, 
associated with very young age, no association to the other common oncogenic 
transcripts, and a proliferation/mitosis signature, whereas the MYB
dup abnormality can 
be found in association with other T-ALL subtypes. 
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Discussion 
The C-MYB gene has been a candidate oncogene in human for years, based on its 
homology with the viral transforming oncogene v-Myb,
12-17 frequent targeting by 
retroviral insertions in mouse,
18-23 and its major role in hematopoiesis.
3-11 However, 
there has been a striking lack of genomic involvement in human cancer, making C-
MYB oncogenic role questionable in human, and a general view has been that it could 
be expressed as a reflection of the immature and proliferative stages of neoplastic 
cells rather than to be causal in cancer.
23,28,30 Here we report for the first time recurrent 
abnormalities of the C-MYB locus by two distinct types of genomic abnormalities in 
human T-cell lymphoblastic leukemia, with a deregulated expression with respect to 
other T-ALLs. These results point out again the C-MYB gene as a strong candidate 
oncogene in human neoplasia. 
First, we detected and characterized fully a recurrent t(6;7)(q23;q34) reciprocal 
translocation. A few t(6;7) cases had been reported in karyotype studies of acute 
leukemias, but partner genes were largely unresolved (Mitelman Database of 
Chromosome Aberrations in Cancer).
60-62 Here, we showed that this translocation 
juxtaposed the TCRB and the C-MYB loci, and localized precisely the breakpoints at 
the molecular level. It should be noted that the t(6;7) translocation can be missed due 
to the subtelomeric location of the breakpoints and frequent poor morphology of T-ALL 
karyotypes. Indeed, we identified t(6;7) cases that were undiscovered previously using 
locus-specific FISH and molecular approaches. This translocation was found in very 
young children compared with the median age for T-ALL; hence, it may be a common 
abnormality in these patients. Systematic searches in young children T-ALLs will allow 
evaluation of the occurrence of C-MYB abnormalities in this group of patients. 
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Using systematic genome-wide copy number analysis, we identified a second 
recurrent genomic abnormality involving C-MYB in T-ALL, as a short genomic tandem 
duplication. This cryptic abnormality was undetectable using conventional cytogenetics 
and locus-specific FISH, which may explain why it was not identified in previous 
studies. We mapped precisely the MYB
dup to a 230kb region that contained the C-MYB 
gene using high density oligonucleotide arrays-CGH. Local tandem duplication was 
demonstrated using Fiber-FISH. These data highlight the strength of high-density 
array-CGH to identify cryptic copy-number abnormalities in leukemia, as was shown 
recently for the short LMO2 activating deletions in T-ALL.
59 Importantly, we 
demonstrated that the duplication was somatic and not due to one of the constitutional 
copy-number variations (CNVs) that were recently discovered to be relatively common 
in the human genome.
55-57 For this purpose, the availability of samples from the same 
patients in remission, which allowed paired constitutional and tumor analysis was 
invaluable (Figure 2B). Interestingly, the MYB
dup abnormality was frequently found in 
association with the known classifying oncogene transcripts (SIL-TAL, CALM-AF10, 
MLL-ENL, TLX1, TLX3),
37,38 which suggests that MYB
dup could be an additional 
oncogenic event.  
In contrast with the MYB
dup abnormality, clinical and biological data suggest that the 
TCRB-MYB translocation defines a new T-ALL subtype. Strikingly, patients with this 
translocation were very young (no adult; median age 2.2 years old) compared with the 
age range of T-ALL patients. Moreover, the ectopic transcripts that have been 
associated previously to the principal T-ALL subtypes
37,38 were not found in these 
cases, which supports further the view that this rearrangement is associated with 
distinct oncogenic pathways. Co-clustering of these cases with T-cell lines and normal 
thymus sample in a subgroup that is characterized by a high expression of cell cycle, 
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cell proliferation, and mitosis genes suggests a specific related biology (Figure 5, 
Supplemental Figure S5 and Table ST2).  
The c-Myb locus is known as a frequent insertion site in retrovirus-mediated 
oncogenesis in animals.
19,21-23 A detailed map of the mouse insertion sites based on 
the RTCG database and comparison with human data, shows that the c-Myb 
insertions mimic the genomic abnormalities here described in human leukemia (Figure 
3), and provides new validation of the power of these experimental approaches in 
animals to pinpoint human oncogenes. In all, genomic data in mouse and human 
involve a genomic region encompassing the c-Myb gene, with retroviral sites at both 
sides of the c-Myb gene in mouse, which suggests that this gene is a major oncogenic 
target in this chromosomal region. Three other genes, namely AHI1 (Abelson Helper 
Integration), ALDH8A1 (aldehyde dehydrogenase 8 family, member A1), and HBS1L 
(HBS1-like, S. cerevisiae), are located by this genomic region. The AHI1 gene was 
disrupted in two out of six t(6;7) T-ALL cases. AHI1 is a WD40 and SH3-containing 
protein which has a complex pattern of isoforms.
63 It was found to be mutated in a 
congenital brain malformation syndrome known as Joubert syndrome,
64 and was 
investigated as a potential oncogene at retroviral insertions Ahi1 in Abl
+ mice, and in 
human leukemic cell lines and Ph+ samples.
63,65 Although we found no deregulation of 
AHI-1 gene expression, or of the other genes of the region, in the t(6;7) or in the 
MYB
dup T-ALL cases (Supplemental Figure S3), the possibility remains that AHI-1 
gene could play a role as an oncogenic cofactor, in a “one hit, two targets” genomic 
event. Comprehensive c-Myb and Ahi1 deregulation in cellular and animal models 
should be useful to investigate this issue.  
The molecular characterization of the six TCRB-MYB cases that was performed in the 
present work showed that this translocation juxtaposed the Cβ enhancer in the vicinity 
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of C-MYB and suggested transcriptional deregulation. In MYB
dup cases, copy number 
gain could be associated with reinforced C-MYB expression. Notably, the 
transcriptional consequences of the C-MYB genomic abnormalities appear unusual 
considering classical models of clearly ectopic oncogene expression, as seen in TLX1 
and TLX3 cases for instance. Considering that C-MYB is expressed at high levels in 
normal thymus, it is likely that it is a strong and sustained, rather than ectopic, 
expression that may be oncogenic. It has been previously reported in mice that c-Myb 
levels are tightly regulated throughout hematopoietic differentiation, including during T-
cell differentiation, with brief up and down level changes that regulate transition 
between differentiation stages, and a final down-regulation.
4,6-11 Abrogation of subtle 
levels of C-MYB into a stable massive expression due to TCRB regulatory sequences 
is likely to disturb progression through T-cell differentiation. This view is strongly 
supported by our finding that C-MYB expression was skewed massively towards 
single allele expression in the TCRB-MYB  translocated cases, which suggests a 
cellular attempt to down regulate C-MYB in these cases (Figure 4C). In the MYB
dup 
cases, an increase of C-MYB expression related to copy number gain may also 
reinforce oncogenic pathways. For both types of abnormality, in vitro and in vivo 
models should be useful to investigate the role of c-Myb in T-cell oncogenesis.  
A number of published reports have shown that C-MYB knock-down by antisense 
inhibit the in vitro growth of leukemic cells, including T-cell lines.
66-68 Although these 
experiments have to be confirmed in primary T-ALL samples using new silencing 
strategies, they suggest that C-MYB expression is necessary for the growth of 
leukemic T cells. Interestingly, C-MYB  expression was recently involved in an 
oncogenic  MLL  → HOXA → C-MYB transcriptional pathway, which suggests that 
indirect biallelic stimulation of C-MYB could also be involved in oncogenic pathways.
69  
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In conclusion, we report for the first time a recurrent somatic involvement of the C-
MYB locus in human leukemia due to two distinct genomic events, TCRB-associated 
translocation and cryptic duplication of a short genome region, and leading to 
deregulated C-MYB expression. Moreover, a new T-ALL clinico-biological entity has 
been here identified which associates a very young age, the t(6;7) TCRB-MYB 
translocation, no association with other common oncogenic transcripts, and a 
proliferation/mitosis expression signature. These results suggest that C-MYB could 
play an oncogenic role in T-ALL, and point to this gene as a potential target for 
therapeutic intervention in human malignancies. 
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Table 1. Patient and molecular data on C-MYB rearranged T-ALL cases 
 
 
 
  Case  Sex Age Oncogenic  CDKN2A/p16/ARF NOTCH1 
  No    transcripts
a deletion
b mutations
c
 
 
t(6;7) TCRB-MYB cases 
 
 TL92  M  1.1  Neg  +  HD-N 
 TL93  F  1.3  Neg  +  wt 
 TL34  M  1.8  Neg  -  wt 
 T142  F  2.5  Neg  +  PEST 
 UPN5846  F  2.9  Neg  +  HD-N 
 TL33  F  10  Neg  +  PEST 
 
 
MYB
dup cases 
 
 TL38  M  5  MLL-ENL  -  wt 
 TL29  F  6  SIL-TAL  +  HD-N 
 TL77  F  8  Neg  +  wt 
 TL61  M  10  TLX3  +  PEST 
 TL66  M  16  TLX3  +  PEST 
 TL40  M  17  CALM-AF10  +  HD-N + PEST 
 TL76  M  24  Neg  -  HD-N 
 TL49  M  40  TLX1  +  HD-C 
 TL59  M  45  TLX1, NUP214-ABL1  +  wt 
 TL01  F  50  Neg  +  wt 
 TL63  F  52  TLX3  +  HD-N + PEST 
 CCRF-CEM  na  na  SIL-TAL  +  HD-N 
 MOLT4  na  na  Neg  +  HD-N + PEST 
 
 
 
Notes and abbreviations. M, male; F, female; na, not applicable. Cases are ordered by increasing age 
in the TCRB-MYB, and MYB
dup cases, respectively.
a Oncogenic transcripts searched for were as follows: 
SIL-TAL, TLX1, TLX3, HOXA, CALM-AF10, MLL, and NUP214-ABL1 fusions transcripts; 
b CDKN2A/p16/ARF locus 
analysis: + deletion detected, - no deletion detected; 
c NOTCH1 mutations were searched in exons 26, 
27 and 34, encoding N-terminal part of heterodimerization domain (HD-N), C-terminal part of 
heterodimerization domain (HD-C) and PEST domain, respectively; wt, wild type. Immunophenotypic data 
of the 6 TCRB-MYB cases are shown in Supplementary Figure S6. 
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Titles and legends to figures  
 
Figure 1. A recurrent translocation t(6;7)(q23;q34) in T-ALL involves the TCRB 
and C-MYB loci. (A) Partial R-banded karyotype with translocation t(6;7)(q23;q34). 
(B) Left panel, FISH whole chromosome painting of chromosomes 6 (green) and 7 
(red) on metaphases from leukemic cells confirmed the reciprocal translocation t(6;7). 
Right panel, dual-color FISH analysis of the TCRB locus using TCRB-flanking probes 
(centromeric, CTD-3092H9 labelled in red, telomeric, RP11-168I15, labelled in green). 
Dissociation of the probes in leukemic cells with t(6;7) demonstrated the involvement 
of the TCRB locus as partner of the translocation. (C) Derivative sequences of 
t(6;7)(q23;q34) breakpoints in case TL34 and corresponding germline sequences. 
Recognition sequence signal (RSS) heptamer and putative heptamer-like sequence 
are indicated according to consensus;
54 untemplated nucleotides (N-diversity) are 
typed in lowercase. GL indicates germline; der, derivative chromosomes. Breakpoint 
sequences for cases T142 and UPN5846 are shown in Supplemental Figure S1. (D) 
Southern blot mapping of the translocation breakpoint in case TL92 using a 6q23.3 
probe derived from BAC RP11-388E23. Germline (GL) and TL34 (TCRB-MYB) DNAs 
are shown as negative and positive controls, respectively. EcoRI rearranged bands 
are shown by arrows. (E) Interphasic FISH screening of T-ALL using flanking C-MYB 
locus probes RP11-845K5 (green) and RP11-184J4 (red) identified additional MYB-
translocated cases TL33 and TL93, further shown to juxtapose the TCRB and C-MYB 
loci using combinations of FISH probes. (F) Schematic representation of the der(6) 
genomic region of t(6;7), according to data from the IMGT database and the UCSC 
Genome Bioinformatics site, and to the DNA derivative sequence of the breakpoint 
region in case T142. An arrow indicates the breakpoint (BP). 
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Figure 2. Identification of recurrent somatic genomic duplications at the C-MYB 
locus in T-ALL. (A) Global representation of large-scale analysis of genomic copy 
number using a 4K array-CGH in MOLT4 cell line (upper panel) and TL63 primary T-
ALL case (lower panel). DNA copy gain at the C-MYB locus at 6q23 is indicated, as 
well as the DNA copy loss at the CDKN2A/p16/ARF locus at 9p21 as an example. (B) 
Compared analysis of array hybridization using as normal DNA either a healthy 
subject DNA (control) or germline DNA (GL) of the same patient as DNA reference. 
This analysis allowed us to distinguish copy-number variations (CNVs) and somatic 
genomic imbalances. As an example, a CNV at 5p15 was resolved in the TL26 and 
TL29 cases (a gain was observed when the leukemic DNA was co-hybridized with an 
unrelated control DNA, but it disappeared using paired leukemic and GL controls). A 
somatic loss of CDKN2A/p16/ARF was evidenced in both the TL26 and TL29 cases, 
because the imbalance persisted after cohybridization with paired control; similarly the 
somatic gain at the 6q23/C-MYB locus was confirmed in case TL29. For each 
BAC/PAC of the array, gains were represented in red, losses in green, and balanced 
signals in yellow. (C) Copy-number analysis using a very high density oligonucleotide 
array (Agilent), focused on the C-MYB region, enabled the minimal region of genomic 
gain to be mapped to approximately 230 Kb. Right panel, a 6 Mb-sized copy gain 
region was found in case TL01; left panel, a short minimal genomic gain including the 
C-MYB gene was evidenced in case TL29 (array-cgh performed with paired leukemic 
and GL DNAs). The genomic region of gain of chromosome 6 is magnified, with the 
horizontal cursor (blue) pointing out the C-MYB gene (shown in red in the right panel). 
The so-called ‘moving average’ ratio between leukemic and GL DNA appears as a 
blue line in case TL01, and a brown line in case TL29. Two copies (alleles) of the 
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locus appear as a moving average close to 0, whereas a DNA copy gain of an allele 
shifts the line close to ratio +0.5 along the corresponding genomic region (D) 
Interphasic C-MYB FISH using the RP1-32B1 (green) and RP3-388E23 (red) probes 
in the MYB
dup cases showed no extra signal (except in the complex MOLT4 
pseudotetraploid cell line, not shown), which suggests local duplication. (E) Fiber-FISH 
analysis using C-MYB locus probes RP11-55H4 (red) and RP11-166A21 (green) 
demonstrated a local duplication (bottom); the normal allele is shown on the top. 
 
Figure 3. Genomic rearrangements target the C-MYB locus in both human and 
mouse T-cell leukemias. Representation of the C-MYB locus in both the human and 
mouse genomes according to the UCSC database; note that the orientation of the 
mouse locus was inverted in this figure in order to maintain the orientation of the 
human locus and facilitate comparison. The ALDH8A1,  HSB1L,  C-MYB, and AHI1 
genes are shown according to annotations in UCSC. The genomic rearrangements we 
described in this work in human T-ALL are indicated: breakpoints (vertical black 
arrows) of the six TCRB-MYB cases, and duplicated genomic regions (horizontal black 
bars) in the 13 T-ALL cases (TL01, TL29, TL38, TL40, TL49, TL59, TL61, TL63, TL66, 
TL76, TL77, CCRF-CEM, and MOLT4). The darker horizontal bottom line refers to a 
MYB
dup in addition to a larger 6q gain in Molt4, leading to extracopies of the locus. 
Two FISH probes that were used for breakpoint mapping are shown. On the mouse 
genome (lower panel), all the reported retroviral insertion sites of T-cell leukemias are 
indicated (vertical black arrows), based on data from the Retrovirus Tagged Cancer 
Gene Database. 
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Figure 4. Expression analysis of the C-MYB gene in T-ALL. (A) C-MYB transcript 
levels were quantified by RQ-PCR in a series of samples: normal bone marrow (BM, 
n=2), PHA-stimulated PBL (PHA-PBL, n=1), growing fibroblasts (n=1), thymus (n=1), 
t(6;7) TCRB-MYB cases (n=5, one case not available), MYB
dup (n=13), other T-ALL 
(n=54) as indicated. Median value is indicated by a horizontal bar for each group (B) 
Sequencing of C-MYB in TL92 tumor genomic DNA showed heterozygosity for a 
polymorphic T8/9 repetition in the 3’UTR region; sequencing of the TL92 leukemic 
cDNA in this TCRB-MYB case demonstrated a skewed allelic expression. (C) Analysis 
of the T8/9 polymorphic microsatellite using fragment size analysis. Informative 
patients without C-MYB rearrangement (n=27) showed balanced expression; 
informative patients with t(6;7) translocation (n=3; TL33, TL34, and TL92) showed a 
skewed expression of one C-MYB allele; and informative patients with MYB
dup (n=7) 
showed an imbalanced profile of both leukemic genomic DNA and leukemic cDNA. 
 
Figure 5. Profiling of the TCRB-MYB cases by large-scale gene expression 
analysis. (A) Heat map representation of the hierarchical clustering of genes and 
samples using expression values for genes expressed differentially between the four 
TCRB-MYB cases and the SIL-TAL1,  TLX1 and TLX3 cases (gene list in 
Supplemental Table ST1). One thymus sample and four T-cell lines are also included 
in the analysis. Cytogenetic/genomic annotations are as follows: Y, TCRB-MYB; L, 
TLX3; E, TLX1; S, SIL-TAL1. Oncogenic groups: Y, TCRB-MYB; H, HOX-related; T, 
TAL-related; c, cell lines.
38 Oncogene expression levels are shown as follows: TAL1 
positive, range from 1 to 6; -, not analyzed; other are negative; LMO1 and LMO2: P, 
positive; -, not analyzed; other are negative. Data were normalized as described
38 and 
redundant probe sets were masked. The four TCRB-MYB cases (boxed in pink) are 
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included in a cluster of cases indicated in blue, together with 3 cell lines (CCRF-CEM, 
Jurkat and HSB2), the normal thymus sample, and a SIL-TAL case (TL29). 
Representative genes from the three major clusters are shown, and ectopic genes are 
indicated in red. (B) Average expression (+/- SD) of the genes that characterize the 
TCRB-MYB and cell line cluster. This cluster is specifically enriched in genes linked to 
cell cycle, cell proliferation and mitosis, according to Gene Ontology (GO) terms (see 
Supplemental Table ST2). 
  
 
 
 
 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From    - 29 - 
References 
1. Weston K. Myb proteins in life, death and differentiation. Curr Opin Genet Dev. 1998;8:76-81. 
2. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 
1999;18:3017-3033. 
3. Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal 
hepatic hematopoiesis. Cell. 1991;65:677-689. 
4. Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G, Frampton J. Progression 
through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. Embo J. 
2003;22:4478-4488. 
5. Sandberg ML, Sutton SE, Pletcher MT, et al. c-Myb and p300 regulate hematopoietic stem cell 
proliferation and differentiation. Dev Cell. 2005;8:153-166. 
6. Sakamoto H, Dai G, Tsujino K, et al. Proper levels of c-Myb are discretely defined at distinct steps of 
hematopoietic cell development. Blood. 2006;108:896-903. 
7. Badiani P, Corbella P, Kioussis D, Marvel J, Weston K. Dominant interfering alleles define a role for 
c-Myb in T-cell development. Genes Dev. 1994;8:770-782. 
8. Allen RD, 3rd, Bender TP, Siu G. c-Myb is essential for early T cell development. Genes Dev. 
1999;13:1073-1078. 
9. Pearson R, Weston K. c-Myb regulates the proliferation of immature thymocytes following beta-
selection. Embo J. 2000;19:6112-6120. 
10. Bender TP, Kremer CS, Kraus M, Buch T, Rajewsky K. Critical functions for c-Myb at three 
checkpoints during thymocyte development. Nat Immunol. 2004;5:721-729. 
11. Lieu YK, Kumar A, Pajerowski AG, Rogers TJ, Reddy EP. Requirement of c-myb in T cell 
development and in mature T cell function. Proc Natl Acad Sci U S A. 2004;101:14853-14858. 
12. Duesberg PH, Bister K, Moscovici C. Genetic structure of avian myeloblastosis virus, released from 
transformed myeloblasts as a defective virus particle. Proc Natl Acad Sci U S A. 1980;77:5120-5124. 
13. Souza LM, Strommer JN, Hillyard RL, Komaromy MC, Baluda MA. Cellular sequences are present 
in the presumptive avian myeloblastosis virus genome. Proc Natl Acad Sci U S A. 1980;77:5177-5181. 
14. Baluda MA, Reddy EP. Anatomy of an integrated avian myeloblastosis provirus: structure and 
function. Oncogene. 1994;9:2761-2774. 
15. Lipsick JS, Wang DM. Transformation by v-Myb. Oncogene. 1999;18:3047-3055. 
16. Badiani PA, Kioussis D, Swirsky DM, Lampert IA, Weston K. T-cell lymphomas in v-Myb transgenic 
mice. Oncogene. 1996;13:2205-2212. 
17. Davies J, Badiani P, Weston K. Cooperation of Myb and Myc proteins in T cell lymphomagenesis. 
Oncogene. 1999;18:3643-3647. 
18. Shen-Ong GL, Potter M, Mushinski JF, Lavu S, Reddy EP. Activation of the c-myb locus by viral 
insertional mutagenesis in plasmacytoid lymphosarcomas. Science. 1984;226:1077-1080. 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From    - 30 - 
19. Hwang HC, Martins CP, Bronkhorst Y, et al. Identification of oncogenes collaborating with p27Kip1 
loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci U S A. 
2002;99:11293-11298. 
20. Kanter MR, Smith RE, Hayward WS. Rapid induction of B-cell lymphomas: insertional activation of 
c-myb by avian leukosis virus. J Virol. 1988;62:1423-1432. 
21. Kim R, Trubetskoy A, Suzuki T, Jenkins NA, Copeland NG, Lenz J. Genome-based identification of 
cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J Virol. 2003;77:2056-
2062. 
22. Lund AH, Turner G, Trubetskoy A, et al. Genome-wide retroviral insertional tagging of genes 
involved in cancer in Cdkn2a-deficient mice. Nat Genet. 2002;32:160-165. 
23. Wolff L. Myb-induced transformation. Crit Rev Oncog. 1996;7:245-260. 
24. Harper ME, Franchini G, Love J, Simon MI, Gallo RC, Wong-Staal F. Chromosomal sublocalization 
of human c-myb and c-fes cellular onc genes. Nature. 1983;304:169-171. 
25. Slamon DJ, Boone TC, Murdock DC, et al. Studies of the human c-myb gene and its product in 
human acute leukemias. Science. 1986;233:347-351. 
26. Barletta C, Pelicci PG, Kenyon LC, Smith SD, Dalla-Favera R. Relationship between the c-myb 
locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science. 1987;235:1064-1067. 
27. Siegert W, Beutler C, Langmach K, Keitel C, Schmidt CA. Differential expression of the 
oncoproteins c-myc and c-myb in human lymphoproliferative disorders. Eur J Cancer. 1990;26:733-737. 
28. Ganter B, Lipsick JS. Myb and oncogenesis. Adv Cancer Res. 1999;76:21-60. 
29. Introna M, Golay J. How can oncogenic transcription factors cause cancer: a critical review of the 
myb story. Leukemia. 1999;13:1301-1306. 
30. Weston K. Reassessing the role of C-MYB in tumorigenesis. Oncogene. 1999;18:3034-3038. 
31. Lutwyche JK, Keough RA, Hughes TP, Gonda TJ. Mutation screening of the c-MYB negative 
regulatory domain in acute and chronic myeloid leukaemia. Br J Haematol. 2001;114:632-634. 
32. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-
1548. 
33. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 
2005;23:6306-6315. 
34. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics 
of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496-1510. 
35. Breit TM, Wolvers-Tettero IL, van Dongen JJ. Phenotypic and genotypic characteristics of human 
early T-cell differentiation: the T-cell acute lymphoblastic leukaemia model. Res Immunol. 
1994;145:139-143; discussion 155-138. 
36. Asnafi V, Beldjord K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute 
lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. 
Blood. 2003;101:2693-2703. 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From    - 31 - 
37. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic 
pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75-87. 
38. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks 
defining human acute T-cell leukemia (T-ALL). Blood. 2005;106:274-286. 
39. Asnafi V, Radford-Weiss I, Dastugue N, et al. CALM-AF10 is a common fusion transcript in T-ALL 
and is specific to the TCRgammadelta lineage. Blood. 2003;102:1000-1006. 
40. Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-
lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003;102:262-268. 
41. Nagel S, Kaufmann M, Drexler HG, MacLeod RA. The cardiac homeobox gene NKX2-5 is 
deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). 
Cancer Res. 2003;63:5329-5334. 
42. Przybylski GK, Dik WA, Grabarczyk P, et al. The effect of a novel recombination between the 
homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the 
NKX2-5 gene. Haematologica. 2006;91:317-321. 
43. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. Multiple tumor-suppressor gene 1 
inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood. 
1996;87:2180-2186. 
44. Gardie B, Cayuela JM, Martini S, Sigaux F. Genomic alterations of the p19ARF encoding exons in 
T-cell acute lymphoblastic leukemia. Blood. 1998;91:1016-1020. 
45. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute 
lymphoblastic leukemia. Science. 2004;306:269-271. 
46. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell 
acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6:347-359. 
47. Clappier E, Cuccuini W, Cayuela JM, et al. Cyclin D2 dysregulation by chromosomal translocations 
to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia. 2006;20:82-86. 
48. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute 
lymphoblastic leukemia. Nat Genet. 2004;36:1084-1089. 
49. Downing JR, Mullighan CG. Tumor-specific genetic lesions and their influence on therapy in 
pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006:118-122. 
50. Lebofsky R, Bensimon A. Single DNA molecule analysis: applications of molecular combing. Brief 
Funct Genomic Proteomic. 2003;1:385-396. 
51. Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome 1p losses with opposite significance 
in gliomas. Ann Neurol. 2005;58:483-487. 
52. La Rosa P, Viara E, Hupe P, et al. VAMP: visualization and analysis of array-CGH, transcriptome 
and other molecular profiles. Bioinformatics. 2006;22:2066-2073. 
53. Marculescu R, Vanura K, Le T, Simon P, Jager U, Nadel B. Distinct t(7;9)(q34;q32) breakpoints in 
healthy individuals and individuals with T-ALL. Nat Genet. 2003;33:342-344. 
54. Marculescu R, Vanura K, Montpellier B, et al. Recombinase, chromosomal translocations and 
lymphoid neoplasia: targeting mistakes and repair failures. DNA Repair (Amst). 2006;5:1246-1258. 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From    - 32 - 
55. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. 
Science. 2004;305:525-528. 
56. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat 
Genet. 2004;36:949-951. 
57. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. 
Nature. 2006;444:444-454. 
58. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene 
expression profiling. Blood. 2003;102:2951-2959. 
59. Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion 
del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic 
leukemia. Blood. 2006;108:3520-3529. 
60. Chan LC, Ha SY, Ching LM, et al. Cytogenetics and immunophenotypes of childhood acute 
lymphoblastic leukemia in Hong Kong. Cancer Genet Cytogenet. 1994;76:118-124. 
61. Heerema NA, Sather HN, Sensel MG, et al. Frequency and clinical significance of cytogenetic 
abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer 
Group. J Clin Oncol. 1998;16:1270-1278. 
62. Sinclair P, Harrison CJ, Jarosova M, Foroni L. Analysis of balanced rearrangements of chromosome 
6 in acute leukemia: clustered breakpoints in q22-q23 and possible involvement of c-MYB in a new 
recurrent translocation, t(6;7)(q23;q32 through 36). Haematologica. 2005;90:602-611. 
63. Jiang X, Hanna Z, Kaouass M, Girard L, Jolicoeur P. Ahi-1, a novel gene encoding a modular 
protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations. J 
Virol. 2002;76:9046-9059. 
64. Ferland RJ, Eyaid W, Collura RV, et al. Abnormal cerebellar development and axonal decussation 
due to mutations in AHI1 in Joubert syndrome. Nat Genet. 2004;36:1008-1013. 
65. Jiang X, Zhao Y, Chan WY, et al. Deregulated expression in Ph+ human leukemias of AHI-1, a gene 
activated by insertional mutagenesis in mouse models of leukemia. Blood. 2004;103:3897-3904. 
66. Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B. G1/S transition in normal 
human T-lymphocytes requires the nuclear protein encoded by c-myb. Science. 1989;245:180-183. 
67. Calabretta B, Sims RB, Valtieri M, et al. Normal and leukemic hematopoietic cells manifest 
differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study 
relevant to bone marrow purging. Proc Natl Acad Sci U S A. 1991;88:2351-2355. 
68. Gewirtz AM. Myb targeted therapeutics for the treatment of human malignancies. Oncogene. 
1999;18:3056-3062. 
69. Hess JL, Bittner CB, Zeisig DT, et al. c-Myb is an essential downstream target for homeobox-
mediated transformation of hematopoietic cells. Blood. 2006;108:297-304. 
 
 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Figure 1
TGTAACATTGTGGGGACAGGGGGCCACAATGATTCAACTCTA    GL 7q35
|||||||||||||||||||||
TGTAACATTGTGGGGACAGGGtgACCTCGGAAAGTCTGAAGCTT  der(7)
|||||||||||||||||||||
GGCTGTGTCACTGTGTGAACCTCGGAAAGTCTGAAGCTT  GL 6q23
GGCTGTGTCACTGTGTGAACCTCGGAAAGTCTGAAGCTTATCA   GL 6q23
|||||||||||||
GGCTGTGTCACTGcctctcccCTATGGCTACACCTTCGGTTCGG  der(6)
|||||||||||||||||||||||
GGCTATATTCTTATGTGCTAACTATGGCTACACCTTCGGTTCGG  GL 7q35
der(7)
7
6
der(6)
AB
E
D C
(Case TL34)
Case TL34
t(6;7)(q23;q34)
GL TL92 TL34
Case TL92
F
TCRB probes
MYB probes
Case TL93
Enhancer Eβ C-MYB
der(6) centromere telomere
TCRB locus
BP
6.5
9.4
WM (kb)
7-mer
Dβ1
7-mer
Jβ1.2
7-mer-like
7-mer
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Figure 2
A
B
D
C
6 Mb gain
(TL01)
230 kb gain
(TL29)
TL63
MYB
gain
MYB
gain
MOLT4
CDKN2A/ARF
loss
E
TL29
CDKN2A/ARF
loss
MYB probes
CCRF-CEM
TL29 GL
TL26 GL
Control
reference DNA :
Tumor DNA :
vs
5p15 CNV
Control
C-MYB locus 
somatic gain in 
case TL29
CDKN2A/p16
somatic loss
Chr. position Genes
5 16.615.438 1.01 1.02 0.99 0.99
5 17.465.576 1.23 1.09 1.25 1.02
5 17.465.577 1.20 1.09 1.31 1.01
5 19.222.468 1.04 1.04 1.03 0.98
6 134.023.947 0.1 0.98 0.97 0.92
6 135.154.013 HBS1L 0.94 0.98 1.02 1.08
6 135.481.982 0.92 0.99 1.27 1.36
6 135.482.463 0.94 1.03 1.33 1.30
6 135.533.533 C-MYB 0.99 1.01 1.41 1.36
6 135.575.483 0.94 1.05 1.34 1.34
6 135.575.523 AHI1 0.91 1.02 1.33 1.31
6 136.260.344 1.03 1.01 1.05 1.05
6 136.840.699 1.02 0.1 0.96 1.02
6 136.892.735 1.01 1.01 0.94 1.01
9 18.672.062 1.04 0.97 0.99 0.99
9 20.172.510 1.03 1.02 0.60 0.64
9 21.733.188 0.78 0.77 0.88 0.85
9 21.851.910 CDKN2A 0.56 0.52 0.65 0.63
9 22.418.310 0.94 0.91 1.09 1.06
TL26 TL29 0 +1 0 +1
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Figure 3
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From Figure 4
C
A
B
TL92
t(6;7)
Leukemic 
cDNA
TL29
MYBdup
96
96 100 98 102
100 98 102 96 100 98 102
96 100 98 102
96 100 98 102
Polymorphic 
T8/9 repetition
Heterozygous genomic DNA
Skewed expression
TL92
TL12
control
T-ALL
96 100 98 102
Leukemic 
genomic DNA
Leukemic 
genomic DNA
Leukemic 
cDNA
0,1
1
10
10 0
10 0 0
N
u
m
b
e
r
 
o
f
 
C
-
M
Y
B
t
r
a
n
s
c
r
i
p
t
 
c
o
p
i
e
s
 
r
e
l
a
t
e
d
 
t
o
 
c
o
n
t
r
o
l
 
g
e
n
e
 
T
B
P
 
BM
PHA-PBL
Fibroblasts
Thymus
other T-ALLs
t(6;7)
MYBdup
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From A
TCRB-MYB
YYYYcc c c T TTT T TT TT T T TT T T T HH HH HH HH HHH HH HHH H HH HH HH HH HH HH YYYYcc c c T TTT T TT TT T T TT T T T TTT T TT TT T T TT T T T HH HH HH HH HHH HH HHH H HH HH HH HH HH HH HH HH HH HH HHH HH HHH H HH HH HH HH HH HH
_ _ 6 2 4 _ 4 _ 1 5 2 3 1 1 1 3 4 2 2 2 1 5
_ _ P P P _ _ P P P P
P P _ P P P _ P P P _ P P P P P P P P
Cytogenetics SS SS SS SS S S S S SS S SS E E EEEEEEEE E LLL L L LLLLLLLLLLLLL Y YYY
LMO1
LMO2
Oncogenic group, cell lines
TAL1
T
L
5
0
T
L
7
5
T
L
6
5
T
L
6
5
r
T
L
5
7
T
L
6
4
T
L
5
6
T
L
5
4
T
L
5
9
T
L
5
2
T
L
5
5
T
L
4
9
T
L
5
1
T
L
5
3
T
L
6
2
T
L
5
8
T
L
6
7
r
T
L
6
7
T
L
7
3
T
L
7
4
T
L
7
2
T
L
6
9
T
L
7
1
T
L
6
8
T
L
7
0
T
L
6
1
T
L
6
0
T
L
6
3
T
L
6
6
J
u
r
k
a
t
T
L
9
2
T
L
3
3
T
L
9
3
T
L
3
4
M
o
l
t
4
C
E
M
T
h
y
m
u
s
T
L
2
9
H
S
B
2
T
L
3
5
T
L
0
9
T
L
0
4
T
L
1
4
T
L
2
0
T
L
1
0
T
L
0
8
T
L
0
8
r
T
L
1
7
T
L
0
5
T
L
1
6
T
L
0
3
T
L
1
3
T
L
0
5
r
T
L
2
6
SCG2
TLX1
ETS2
RANBP2
TRG@
IL7R
FLT3
TLX3
CCND2
SIX6
KIFC3
NKX3-1
PTRF
ALDH1A2
IL9R
TAL1
IRX5
-3.0 -2.7 -2.5 -2.2 -2.0 -1.7 -1.4 -1.2 -0.9 -0.7 -0.4 -0.1 0.1 0.4 0.7 0.9 1.2 1.4 1.7 2.0 2.2 2.5 2.7 3.0
SMC4
KIF11
CDCA3
CCNB2
CENPE
MKI67
B
Genes of the cluster:
SMC4, KIF11, KIF14, KIF15, KIF20A, DLG7, ESPL1, 
TOP2A, CDCA3, CDCA8, CDC20, CCNA2, CCNB2, 
CENPE, PLK1, RRM2, MKI67, EXOSC9, DKFZp762E1312
1 23456789
p
at eye syndrome chromosome region, candidate 5
hymosin, beta, identified in neuroblastoma cells Y display range: (-3, 3)
TCRB-MYB
1 Jurkat 
2 TL92
3 TL33
4 TL93
5 TL34
6 Molt4
7 CEM
8 Thymus
9 TL29
TLX1 / TLX3 SIL-TAL1 TCRB-MYB
Figure 5
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 